Vis enkel innførsel

dc.contributor.authorDønnem, Tom
dc.contributor.authorEklo, Katrine
dc.contributor.authorBerg, Thomas
dc.contributor.authorSørbye, Sveinung Wergeland
dc.contributor.authorLønvik, Kenneth
dc.contributor.authorAl-Saad, Samer
dc.contributor.authorAl-Shibli, Khalid Ibrahim
dc.contributor.authorAndersen, Sigve
dc.contributor.authorStenvold, Helge
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorBusund, Lill-Tove
dc.date.accessioned2012-02-24T10:40:14Z
dc.date.available2012-02-24T10:40:14Z
dc.date.issued2011
dc.description.abstractIn recent years, microRNAs (miRNAs) have been found to play an essential role in tumor development. In lung tumorigenesis, targets and pathways of miRNAs are being revealed, and further translational research in this field is warranted. MiR-155 is one of the miRNAs most consistently involved in various neoplastic diseases. We aimed to investigate the prognostic impact of the multifunctional miR-155 in non-small cell lung cancer (NSCLC) patients. Tumor tissue samples from 335 resected stage I to IIIA NSCLC patients were obtained and tissue microarrays (TMAs) were constructed with four cores from each tumor specimen. In situ hybridization (ISH) was used to evaluate the expression of miR-155. There were 191 squamous cell carcinomas (SCCs), 95 adenocarcinomas (ACs), 31 large cell carcinomas and 18 bronchioalveolar carcinomas. MiR-155 expression did not have a significant prognostic impact in the total cohort (P = 0.43). In ACs, high miR-155 expression tended to a significant negative prognostic effect on survival in univariate analysis (P = 0.086) and was an independent prognostic factor in multivariate analysis (HR 1.87, CI 95% 1.01 - 3.48, P = 0.047). In SCC patients with lymph node metastasis, however, miR-155 had a positive prognostic impact on survival in univariate (P = 0.034) as well as in multivariate (HR 0.45, CI 95% 0.21-0.96, P = 0.039) analysis. The prognostic impact of miR-155 depends on histological subtype and nodal status in NSCLC.en
dc.identifier.citationJournal of Translational Medicine 9(2011)en
dc.identifier.issn1479-5876
dc.identifier.otherFRIDAID 828424
dc.identifier.otherdoi: 10.1186/1479-5876-9-6
dc.identifier.urihttp://hdl.handle.net/10037/3864
dc.identifier.urnURN:NBN:no-uit_munin_3586
dc.language.isoengen
dc.publisherJournal of translational medicineen
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.titlePrognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridizationen
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


Tilhørende fil(er)

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel